Baycol withdrawn from market.
SoRelle
R
R
D000924:Anticholesteremic Agents / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004335:Drug and Narcotic Control; D015248:Gemfibrozil / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D011725:Pyridines / Q000009:adverse effects*; D012206:Rhabdomyolysis / Q000139:chemically induced*; D014481:United States; D014486:United States Food and Drug Administration
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin; D015248:Gemfibrozil